Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

William Reece Burns

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7634-9730; OpenAlex author ID A5054307799; NIH RePORTER profile ID 6931567. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
101
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 7 papers, 1 grant

Papers 13

  1. The performance of intraoperative peritoneal washings in detecting pancreatic ductal adenocarcinoma. First author DOI 10.1002/cncy.70126↗
  2. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  3. Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2026.102359↗
  4. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  5. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  6. Patient-derived Organoid Pharmacotyping as a Predictive Tool for Therapeutic Selection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006517↗
  7. Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-0331↗
  8. The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Su… Co-author DOI 10.1097/sla.0000000000006794↗
  9. The Organ-Specific Prognostic Value of TP53 Mutations in Pancreatic Cancer Patients with Oligometastasis Following Surgical Resection. Co-author DOI 10.1097/sla.0000000000006823↗
  10. Association Between Adjuvant Therapy and Survival in Resected Pancreatic Ductal Adenocarcinoma After Different Types and Durations of Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17439-x↗
  11. Notch Signaling Regulates Immunosuppressive Tumor-Associated Macrophage Function in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0037↗
  12. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.06.037↗
  13. Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Co-author DOI 10.1080/2162402x.2021.2001159↗

Grants 1

  1. Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial R01CA197296↗

Closest collaborators

The 25 strongest of 101 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elizabeth M. Jaffee · 4 shared papers, 1 shared grant, 2021–2026 · strength 1.63
  2. Kelly J. Lafaro · 7 shared papers, 2025–2026 · strength 1.54
  3. Lei Zheng · 4 shared papers, 1 shared grant, 2021–2026 · strength 1.51
  4. Jin Peng He · 6 shared papers, 2021–2026 · strength 1.15
  5. Christopher R. Shubert · 5 shared papers, 2025–2026 · strength 1.12
  6. Eric Scott Christenson · 1 shared paper, 1 shared grant, 2026 · strength 1.11
  7. Sagar D. Patel · 3 shared papers, 2025–2026 · strength 0.98
  8. Richard Andrew Burkhart · 5 shared papers, 2021–2026 · strength 0.95
  9. Richard A. Burkhart · 3 shared papers, 2025–2026 · strength 0.68
  10. Brady A. Campbell · 3 shared papers, 2025 · strength 0.67
  11. Samantha R. Guinn · 3 shared papers, 2021–2026 · strength 0.52
  12. Jacquelyn W. Zimmerman · 3 shared papers, 2021–2026 · strength 0.52
  13. Christopher J. VandenBussche · 1 shared paper, 2026 · strength 0.50
  14. Jin He · 2 shared papers, 2026 · strength 0.48
  15. Elana Judith Fertig · 2 shared papers, 2026 · strength 0.43
  16. Norman G. Nicolson · 2 shared papers, 2026 · strength 0.43
  17. Lois A. Daamen · 2 shared papers, 2025–2026 · strength 0.42
  18. Izaak Quintus Molenaar · 2 shared papers, 2025–2026 · strength 0.42
  19. Joseph R. Habib · 2 shared papers, 2025–2026 · strength 0.42
  20. Paul C. M. Andel · 2 shared papers, 2025–2026 · strength 0.42
  21. Christopher Lee Wolfgang · 2 shared papers, 2025–2026 · strength 0.42
  22. Ammar A. Javed · 2 shared papers, 2025–2026 · strength 0.42
  23. Daniel J. Zabransky · 2 shared papers, 2021–2026 · strength 0.28
  24. Luciane Tsukamoto Kagohara · 2 shared papers, 2021–2026 · strength 0.28
  25. Won Jin Ho · 2 shared papers, 2021–2026 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.